Innovation in Protein Therapy for Atherosclerosis——Application of ApoA1
DOI:
https://doi.org/10.61173/ffsbvq26Keywords:
Atherosclerosis, metabolic diseases, lipid metabolism, cholesterol accumulation, ApoA1 modulationAbstract
Atherosclerosis is still the basic cause of metabolic diseases, namely the adnormal lipid metabolism and cholesterol accumulation. As more and more in-depth clinical investigations are being conducted, modulation the high-density lipoprotein (HDL) pathway, particularly the ApoA1, has been particularly attracted attention. Until now, to use these biotechnological functions properly and in management of individuals still poses a challenge. This essay will range from the introduction and discussion on the working and significance of both ApoA1 mimetics and genetically engineered ApoA1, focusing majorly on their functions which involve in enhancing cholesterol efflux and providing anti-inflammatory benefits. Consequently, they as a whole play a role in improving cardiovascular health. The results suggest that novel therapies could just be the epiphany for atherosclerosis cure or reversal. The study delineates the emphasis on protein-based treatments as a move for the future in the management of cardiovascular diseases, which serves as the architecture of subsequent research. However, as time goes on, matching treatment by patients’ genetic and environmental considerations stays to be a roadblock. Next research is set to target unsuitable combinations and those effective and possible in different groups for the development of such strategies.